MannKind (MNKD) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

MannKind MNKD is currently developing the following drugs: Nintedanib Dry Powder Inhalation, Mnkd-201, Basal Insulin, Technosphere Insulin, Mknd-201, Clofazimine Inhalation Suspension, Insulin Degludec, Basal Insulin, Afrezza, Rapid-Acting Insulin Analog, Insulin Degludec, Afrezza Inhalation Powder, Continuous Subcutaneous Insulin Infusion Pump With Automatic Insulin Delivery, Basal Insulin, Afrezza, Rapid-Acting Insulin Analog, Afrezza Dose 1, Afrezza Dose 2, Afrezza Inhalant Product, Treprostinil Inhalation Powder, Afrezza Plus One Drop | Premium, One Drop | Premium, Afrezza, Technosphere Insulin Sar439065 Afrezza, Insulin Lispro, Sar439065, Technosphere Insulin, Usual Care. These drug candidates are in various stages of clinical development as the company works toward FDA approval.